Development of AAV vectors for CF therapy
Development of AAV vectors for CF therapy
批准号:
10319017
负责人:
Chengwen Li
金额:
$38.88万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-12-15 至 2024-11-30
关键词:
AddressAirway DiseaseAnimal ModelBindingBlindnessBloodBlood Coagulation DisordersBlood VesselsCRISPR/Cas technologyCapsidClinical TrialsComplicationCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDNADependovirusDevelopmentDirected Molecular EvolutionDiseaseEpithelial CellsFailureGene DeliveryGenesGenetic DiseasesGenetic EngineeringGenomeHemorrhageHigh PrevalenceHumanIn VitroIncubatedIntravenous ImmunoglobulinsLibrariesLongitudinal StudiesLungLung diseasesMeasurableMediatingMorbidity - disease rateMusMutationOrganPatientsPeptidesPeripheralPersonsPhage DisplayPhenotypePlant RootsPropertyProteinsRegulator GenesSerotypingTechnologyTestingTissuesTransduction GeneVariantVascular PermeabilitiesVectorial capacityViral GenomeViral PackagingVirionadeno-associated viral vectorairway epitheliumapical membranebasebasolateral membranecellular transductioncystic fibrosis airway epitheliacystic fibrosis mousecystic fibrosis patientsdelivery vehicleds-DNAearly phase clinical trialgene therapymortalitymutantneutralizing antibodynovelnovel strategiespulmonary functionrecessive genetic traitsmall moleculesuccesstransduction efficiencyvectorvector-induced
中文摘要
摘要
囊性纤维化(CF)是由CF跨膜传导调节因子(CFTR)基因突变引起的。
气道疾病是发病率和死亡率的主要原因。基因治疗为CF提供了一种潜在的治疗方法。
在基因递送载体中,腺相关病毒(AAV)载体已经在临床上显示出成功。
审判AAV载体也已经在CF患者中通过气道递送进行了基因添加的测试,但没有
可测量的成功可能是由于物理气道屏障和低效的转导。研究表明
在体外,气道上皮细胞通过基底外侧膜进行更高的AAV转导,
初步研究表明,AAV载体的全身给药诱导了更有效的肺
在小鼠中,转导比气道递送更有效。这些发现强烈提示AAV可以阻断气道
上皮细胞通过全身给药。AAV转导在气道上皮细胞中的效率
AAV载体的全身递送通常受到血管屏障的限制,并且AAV载体的高患病率是一个很大的障碍。
AAV中和抗体(Nabs)。在这个建议中,基于我们以前的研究,我们将探索不同的
利用定向进化和AAV病毒体特异性结合肽开发新型AAV载体的策略,
噬菌体展示技术增加AAV载体血管通透性以增强气道中的转导
上皮细胞,并在全身给药后逃避Nabs。最后,新的方法,
该提案将用于向CF小鼠递送对CFTR del 508特异性的优化CRISPR/Cas9,并研究
长期的表型校正。从这些研究中产生的结果将使我们能够制定一个
使用AAV载体介导的基因递送治疗CF患者的有效方法。
.
英文摘要
Abstract
Cystic fibrosis (CF) is caused by mutations of the CF transmembrane conductance regulator (CFTR) gene.
Airway disease is the leading cause of morbidity and mortality. Gene therapy offers a potential cure for CF.
Among gene delivery vehicles, adeno-associated virus (AAV) vectors have demonstrated success in clinical
trials. AAV vectors have also been tested in CF patients via airway delivery for gene addition but without
measurable success perhaps due to physical airway barriers and inefficient transduction. Studies have shown
that higher AAV transduction of airway epithelial cells occur via the basolateral membrane in vitro and our
preliminary study demonstrated that systemic administration of AAV vectors induced much more efficient lung
transduction than airway delivery in mice. These findings strongly suggest that AAV can transduce airway
epithelial cells via systemic administration. The efficiency of AAV transduction in airway epithelial cells after
systemic delivery of AAV vectors is usually restricted by the blood vascular barrier and a high prevalence of
AAV neutralizing antibodies (Nabs). In this proposal, based on our previous studies, we will explore different
strategies to develop novel AAV vectors using directed evolution and AAV virion specific binding peptides via
phage display technology to increase AAV vector vascular permeability for enhanced transduction in airway
epithelial cells and to evade Nabs after systemic administration. Finally, the novel approaches developed in
this proposal will be used to deliver optimized CRISPR/Cas9 specific for CFTR del508 to CF mice and study
the long-term phenotypic correction. The results generated from these studies will allow us to develop an
effective approach to treat CF patients using AAV vector mediated gene delivery.
.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel strategy to block Nabs for AAV gene delivery
-
批准号:10570881
-
项目类别:
-
资助金额:$57.94万
-
财政年份:2022
-
负责人:Chengwen Li
-
依托单位:
Novel strategy to block Nabs for AAV gene delivery
-
批准号:10416627
-
项目类别:
-
资助金额:$57.88万
-
财政年份:2022
-
负责人:Chengwen Li
-
依托单位:
Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion
-
批准号:10546241
-
项目类别:
-
资助金额:$26.11万
-
财政年份:2022
-
负责人:Chengwen Li
-
依托单位:
Development of AAV vectors for CF therapy
-
批准号:10544549
-
项目类别:
-
资助金额:$38.88万
-
财政年份:2020
-
负责人:Chengwen Li
-
依托单位:
Development of AAV vectors for CF therapy
-
批准号:10117463
-
项目类别:
-
资助金额:$38.88万
-
财政年份:2020
-
负责人:Chengwen Li
-
依托单位:
Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion
-
批准号:10079155
-
项目类别:
-
资助金额:$24.93万
-
财政年份:2020
-
负责人:Chengwen Li
-
依托单位:
Novel strategy to block AAV neutralizing anitbody activity
-
批准号:10080225
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2020
-
负责人:Chengwen Li
-
依托单位:
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors
-
批准号:10372097
-
项目类别:
-
资助金额:$62.56万
-
财政年份:2019
-
负责人:Chengwen Li
-
依托单位:
Enhance AAV Liver Transduction with Capsid Immune Evasion
-
批准号:9098885
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2016
-
负责人:Chengwen Li
-
依托单位:
Enhance AAV Liver Transduction with Capsid Immune Evasion
-
批准号:9893176
-
项目类别:
-
资助金额:$6.44万
-
财政年份:2016
-
负责人:Chengwen Li
-
依托单位:
Enhance AAV Liver Transduction with Capsid Immune Evasion
-
批准号:9232972
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2016
-
负责人:Chengwen Li
-
依托单位:
Directed evolution of AAV vectors for hemophilia to evade neutralization
-
批准号:9136222
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2015
-
负责人:Chengwen Li
-
依托单位:
Directed evolution of AAV vectors for hemophilia to evade neutralization
-
批准号:9509528
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2015
-
负责人:Chengwen Li
-
依托单位:
CTL response to AAV Vector
-
批准号:8071320
-
项目类别:
-
资助金额:$1.54万
-
财政年份:2010
-
负责人:Chengwen Li
-
依托单位:
AAV Gene Therapy for AAT deficiency
-
批准号:7696829
-
项目类别:
-
资助金额:$29.6万
-
财政年份:2009
-
负责人:Chengwen Li
-
依托单位:
AAV Gene Therapy for AAT Deficiency
-
批准号:8825344
-
项目类别:
-
资助金额:$31.92万
-
财政年份:2009
-
负责人:Chengwen Li
-
依托单位:
AAV Gene Therapy for AAT Deficiency
-
批准号:8606458
-
项目类别:
-
资助金额:$31.92万
-
财政年份:2009
-
负责人:Chengwen Li
-
依托单位:
CTL response to AAV Vector
-
批准号:8197305
-
项目类别:
-
资助金额:$36.31万
-
财政年份:2009
-
负责人:Chengwen Li
-
依托单位:
CTL response to AAV Vector
-
批准号:7994158
-
项目类别:
-
资助金额:$36.31万
-
财政年份:2009
-
负责人:Chengwen Li
-
依托单位:
AAV Gene Therapy for AAT deficiency
-
批准号:7943012
-
项目类别:
-
资助金额:$29.6万
-
财政年份:2009
-
负责人:Chengwen Li
-
依托单位:
海外基金